The Greatest Story Never Told
“It has never been shown that [Gardasil] prevents cervical cancer,” explains Dr. Blaylock to Adams, noting that Merck’s widely-aired “One Less” television and internet campaign, which insinuates that Gardasil prevents cervical cancer in young girls, is a complete fraud.
Leslie Carol Botha: First of all Gardasil is not a cervical cancer vaccine. Mainstream media is already spinning Kristin’s story by their deliberate use of the words ‘cervical cancer.’ Secondly, no one will know if the HPV vaccines will affect cervical cancer rates for 20 years….. Gardasil is the most incredible hoax on medical consumers – the more one learns – the more absurd the issue.
We are going to be One Less to get the HPV Vaccine Gardasil and Cervarix.
I received an email from my ICAP associate, Christina England today. Her message explained a mystery I have been trying to solve for the past week. My site stats have indicated a large number of hits from Russian ISPs and those visitors spending time investigating my article archive. Christina noted the same site visitor anomalies and traced the traffic back to http://www.oodvrs.ru/article/index.php?id_page=47&id_article=940 and found her article about ICAP communications with the German Scientists of RKI concerning the safety of the HPV vaccines Gardasil and Cervarix. This article tracks back to our papers. It is amazing but our message has been have been translated into Russian. The word is getting out there yippee! Congrats to Christina!
HPV is one causal factor in the development of cervical cancer. Medical researchers note other factors contribute to cervical cancer, such as: Poverty— limited or no access to medical services; tobacco use; eating habits; weakened immune system; hormonal medications; exposure to Diethylstilberstrol (DES); Douching; and Chemical exposure in work environment.
Scottish Conservative health spokeswoman Mary Scanlon said: “Given this new research, it is now incumbent on the Scottish Government and the chief medical officer to review the vaccination program to ensure that it lives up to the expectations of preventing cervical cancer.”
GSK has submitted its response to questions raised by the FDA in their Complete Response Letter, received in December, 2007. In addition, given that final data from GSK’s Phase III pivotal efficacy study, HPV-008, are expected to be available later this year, GSK has decided to augment its application for approval with these data to ensure they are included in the U.S. label. GSK anticipates submitting these data in the first half of 2009. The timing depends on reaching a certain number of cases in order to conduct the final analysis. An FDA action on the application is expected to take up to six months following this submission. Interim data from this study were filed in the original application for the vaccine in March, 2007. The company does not expect that new clinical studies will be required for approval.
